Neutropenia grade ≥ 3 during treatment with docetaxel (DOC) is associated with an improved overall survival (OS): A retrospective analysis of the TAX327 phase III trial

2016-10-01

Annals of Oncology , Volume 27 p. vi256

Additional Metadata
Persistent URL	doi.org/10.1093/annonc/mdw372.39, hdl.handle.net/1765/126459
Journal	Annals of Oncology
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Meisel, A., Vogt, D. R., de Wit, R., de Bono, J., Sartor, O., Eisenberger, M., & Stenner-Liewen, F. (2016). Neutropenia grade ≥ 3 during treatment with docetaxel (DOC) is associated with an improved overall survival (OS): A retrospective analysis of the TAX327 phase III trial. Annals of Oncology, 27. doi:10.1093/annonc/mdw372.39

Publication